Revolution Medicines, Inc. announced that the FDA has approved RASONQUE (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at… read more.
Patients’ responses to questions routinely raised by oncologists may provide important clues about their chances of survival from chronic lymphocytic leukemia (CLL), according to a new study published in the… read more.
HUTCHMED (China) announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China… read more.
A supplemental New Drug Application for approval of Zegfrovy (sunvozertinib) in the 1st-line setting has been accepted by the FDA, supported by positive results from the global WU-KONG28… read more.
Gilead Sciences, Inc. announced that the EC has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable,… read more.
NICE (UK) is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma in adults after 2… read more.
NICE(UK): Acalabrutinib plus venetoclax can be used as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used: i) without obinutuzumab, and ii)… read more.
MSD Inc., Tokyo (known as Merck Inc in the USA and Canada) announced that for the Welireg (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor in combination… read more.
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or… read more.
Positive topline results from the DESTINY-Lung04 phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard… read more.
Merck, known as MSD outside of the United States and Canada, announced the Phase 3 KEYNOTE‑C93 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of… read more.
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
